SEngine Precision Medicine’s mission is to implement the next generation of cancer treatments. By marrying a personalized functional diagnostics assay with the advancement of novel drugs based on synthetic lethality, SEngine is drastically accelerating development of cutting edge treatments. Partnering with pharmaceuticals and leading cancer research institutions, SEngine will guide precision oncology as well as the early stages of drug development.
Sierra Oncology is a clinical stage drug development company advancing targeted therapeutics for the treatment of patients with cancer. Our lead product candidate, SRA737, is a potent, highly selective, orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1). SRA737 is currently in two Phase 1 clinical trials focused on enrolling patients with tumors identified to have genetic aberrations hypothesized to confer sensitivity to Chk1 inhibition via synthetic lethality, as a monotherapy or in combination.
Evotec is a drug-discovery & development solutions company offering the life sciences industry a variety of ways to access drug discovery innovation & development expertise in a time efficient manner, as stand-alone or integrated projects and have the confidence that through creative deal making and high quality alliance and project management, their programmes are in safe hands. The Company operates worldwide and has leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise…[Read More…]